OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued on Monday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $4.25 price target on shares of OncoCyte in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.06.

OncoCyte Trading Down 1.3 %

NASDAQ:OCX opened at $3.08 on Monday. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $4.34. The stock has a fifty day moving average price of $3.08 and a 200-day moving average price of $2.94.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million for the quarter.

Insider Activity at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In related news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrea S. James bought 33,670 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were bought at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer now owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. The disclosure for this purchase can be found here. 1.94% of the stock is currently owned by insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.